Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of July 2021, with a specific transaction notification dated July 14, 2021. The filing serves as a report of a transaction involving a Person Discharging Managerial Responsibilities (PDMR) or a person closely associated with them.
Key Financial Metrics
This filing is a transaction notification and does not contain consolidated financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
- Transaction Type: Acquisition of Ordinary Shares.
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: £14.2600 per share.
- Transaction Volume: 8,484.786 shares.
- Transaction Date: July 12, 2021.
- Exchange: London Stock Exchange (XLON).
Material Changes
The filing details a specific acquisition of shares by Ms. E Walmsley, Chief Executive Officer. The transaction resulted from the re-investment of dividends paid to shareholders on July 8, 2021, on Ordinary Shares held in the Company's Performance Share Plan. These shares are subject to a 2-year holding period. No material changes to the company's overall financial position are reported in this specific filing.
Guidance, Outlook, and Risks
The filing does not contain management commentary, forward-looking guidance, risk factors, or contingencies related to the company's operations or financial outlook. It is strictly a regulatory disclosure of a share transaction.
Key Facts for Investor Verification
- Verify the identity of the PDMR involved: Ms. E Walmsley (Chief Executive Officer).
- Confirm the nature of the transaction: Dividend re-investment under the Performance Share Plan.
- Note the holding restriction: The acquired shares are subject to a 2-year holding period.
- Check the transaction volume and price: 8,484.786 shares acquired at £14.2600 on July 12, 2021.